Dinaciclib
Dinaciclib inhibits CDK1/2/5/9, displaying anticancer chemotherapeutic activity. Dinaciclib is currently in clinical trials as a potential treatment for various cancers. In cellular models of acute leukemias, dinaciclib inhibits cell proliferation. In cellular models of pancreatic cancer, this compound inhibits cell proliferation, motility, and colony formation; in vivo, it decreases tumor growth. Dinaciclib also binds BRD proteins.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18880307
| Cas No. |
779353-01-4 |
|---|---|
| Purity |
≥98% |
| Formula |
C21H28N6O2 |
| Formula Wt. |
396.49 |
| Synonym |
SCH 727965 |
| Appearance |
Yellow to off white powder |
Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835.
Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471.
Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430.
Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.
